Key result
This review summarizes available information on the perioperative management of common and in-development antiplatelet agents for patients with coronary stents undergoing elective surgery.
This review summarizes the available information for balancing the risks of intraoperative bleeding and stent thrombosis when managing antiplatelet therapy perioperatively.
Answers are grounded in this paper and cite their sources.
May inform perioperative antiplatelet decisions in stented patients undergoing elective surgery; leaves open optimal strategies pending prospective trials.
Perioperative management of antiplatelet agents is a common challenge with the increased number of patients requiring long-term therapy following coronary stenting. Debate currently exists regarding if and when to discontinue antiplatelet therapy prior to elective surgery. The delicate balance between decreasing the risk of bleeding intraoperatively and minimizing the risk of stent thrombosis in patients who are already at a high thrombotic risk is a major concern. This article summarizes the information available for perioperative management of common antiplatelet agents, as well as antiplatelet agents in development.
No takes yet. Share an insight, caveat, or question.
Mohr et al. (2012) conducted a review in Patients requiring long-term antiplatelet therapy following coronary stenting. Perioperative management of antiplatelet agents was evaluated. This review summarizes available information on the perioperative management of common and in-development antiplatelet agents for patients with coronary stents undergoing elective surgery.
Synapse has enriched 10 related papers. Consider them for comparative context: